Background: orthostatic hypotension (OH) is a common disabling condition associated with increased morbidity and mortality. Much of the evidence available is derived from younger populations with chronic neurological disease leading to uncertainty for the diagnosis and management of older people. Objective: to provide an overview of recent and emerging evidence for the diagnosis, management and prognosis of OH in older persons. Methods: a narrative review of recent studies, emerging therapies and relevant regulatory updates. Findings: revisions to the diagnostic criteria for OH include the duration of the blood pressure drop, specific criteria for initial and delayed OH and OH with hypertension. Non-drug therapies remain the first-line treatment option and Comprehensive Geriatric Assessment appears to result in lower rates of OH. Recent evidence concerning withdrawal of causative medication is inconsistent. Midodrine has recently become the only licenced medication for OH in the UK. Other emerging treatments include atomoxetine and droxidopa but these require further evaluation. Many other agents may be used but are not supported by high-quality evidence. The increase in mortality associated with OH is less apparent in older people. Summary: OH remains common in older people, the new diagnostic criteria address some of the previous uncertainty but evidence concerning withdrawal of antihypertensives is conflicting. Midodrine is now the only licenced medication for OH in the UK, but non-drug therapies remain first line and fludrocortisone may be considered before midodrine. We may see other agents such as droxidopa becoming increasingly used over the coming years.
Introduction
Orthostatic hypotension (OH) is often a disabling condition, characterised by a reduction in blood pressure (BP) on standing upright. Although there is a great deal of heterogeneity in prevalence studies, it remains a highly prevalent condition affecting approximately 25% of people with type 2 diabetes, 30% of community-dwelling people aged ≥65 years and 70% of people with Parkinson's disease (PD) [1] . An estimated 30% of cases of OH experience dizziness/ light-headedness, however, the true prevalence of symptomatic OH may be greater than this due to its broad range of non-specific symptoms (dizziness, fatigue, loss of concentration, vision disturbance and tremulousness) [2] , which result in a reduced quality of life. Furthermore, OH is associated with an increased risk of myocardial infarction, stroke and death [3, 4] . In this New Horizons article we discuss recently published evidence, emerging therapies and updates to guidelines and regulations concerning OH, with a particular focus on older people.
Diagnosis
Since 1996 the diagnosis of OH has been dependent upon a well-defined drop in BP, a 20 mm Hg drop in systolic pressure and/or a 10 mm Hg drop in diastolic pressure [5] . These criteria may be considered as overly rigid by some [6] , but fortunately the consensus definition was updated in 2011 with the addition of some new criteria [7] :
• OH-a sustained reduction in systolic BP of 20 mm Hg or diastolic BP of 10 mm Hg within three minutes of standing or head-up tilt.
• Initial OH-a rapid, transient drop in systolic pressure of 40 mm Hg and/or diastolic pressure of 20 mm Hg within the first 15 s of standing.
• OH in people with hypertension-a drop in systolic BP of 30 mm Hg or more may be more appropriate for a diagnosis of OH, given the higher baseline.
• Delayed OH-a reduction in orthostatic BP that occurs after 3 min of standing.
It is thought that the 20/10 mm Hg BP drop criteria arose from a small study in 1988 which described the normal BP response to standing in 98 healthy hospital workers [8] . These findings are largely supported by the more recent Irish Longitudinal study on Ageing (TILDA) which characterised the pattern of orthostatic BP in 4475 people aged over 50 years [9] . The resulting normograms show that 5% of men aged 50-59 years have a drop in systolic BP > 20 mm Hg between 30 and 120 s of standing. This prevalence increases for each decade such that 20-25% of men aged over 80 years have a systolic drop >20 mm Hg.
There is no accepted time duration that constitutes a sustained drop in BP. In an attempt to address this, one small retrospective study of 103 people (aged 22-94 years, attending a specialist falls and syncope clinic) compared to 5-year outcomes for those who had a transient (<30 s) reduction in BP with those who had a sustained (>30 s) drop. Those with a sustained BP drop were significantly more likely to have received pharmacological treatment of their OH and were more likely to have died within 5 years [10] . In keeping with this finding are the BP profiles derived from the TILDA study which demonstrate that 95% of BP drops in their older population have recovered/stabilised within 30 s of standing.
Identifying the duration of a short-lived drop is realistically, only possible with continuous BP monitoring. This is particularly true for the diagnosis of initial OH which is practically impossible on intermittent BP measurement, given that it occurs within 15 s of standing. But despite the technological advances in non-invasive, continuous BP monitoring, it remains unknown whether it has any clinical advantage over intermittent BP measurement (with the exception of initial OH). In a study of 326 communitydwelling older adults (aged > 65 years) who underwent tilttesting and continuous BP monitoring, 59% were found to have a drop in BP meeting diagnostic criteria [11] . This is in stark contrast to other studies using intermittent measurements, in which the prevalence ranges from 5 to 30% [1] , raising the possibility of a high false positive rate with continuous monitoring. However, in the absence of a gold standard it will be difficult to fully resolve this issue.
The aforementioned TILDA study found that in 95% of participants undergoing an active stand, the drop in BP occurred within the first 30 s of standing [9] . This confirms the finding of another Irish study in which 110 people (mean age 75) with a clinical diagnosis of OH underwent tilt-table testing with continuous BP monitoring [12] . In almost 70% of the participants, the BP had reached its nadir within 30 s, with almost all reaching a nadir within the first 60 s of standing. These results suggest that when using intermittent BP measurements, the first measurement should be taken within 60 s of standing, ideally within the first 30 s. How frequently the BP should be measured thereafter remains uncertain. For a comprehensive review of evidence for the diagnosis of OH we recommend Frith's recent narrative review [13] .
The use of ambulatory BP measurement is becoming increasingly common, particularly in the field of hypertension; however, its use for OH has not yet been determined. It does not have a diagnostic role, but may be used to evaluate the BP profile in more detail, specifically, the identification of post-prandial hypotension (PPH) and reverse dipping (an increase in nocturnal BP compared to daytime). Reverse dipping may be found in approximately 84% of people with OH, however, it is also a common finding in older people without OH, affecting approximately 20% [14, 15] . Similarly, PPH may be identified on ambulatory BP in 83% of people with OH, but it is not a specific finding, affecting 59% of older people with hypertension [15, 16] . A further use of ambulatory BP is to monitor for hypertension when the withdrawal of antihypertensive medication is undertaken to treat OH. However, there is no guidance or evidence to direct clinical practice in this situation, and as is explained below, evidence for the withdrawal of antihypertensives is conflicting.
Aetiology
When OH is identified, consideration should be made to possible underlying causes which may help direct management. There are no systematic reviews or comprehensive studies collating possible causes of OH, however, potential causes derived from a small prospective study and two narrative reviews, have been listed in Table 1 simply for background information. Unfortunately the majority of evidence we have for the diagnosis and treatment of older people is derived from younger people with neurogenic OH, however, most older people with OH do not have an underlying neurogenic cause [17] . In a recent Dutch study of 242 consecutive older patients attending a falls and syncope clinic, there were no differences in autonomic function between those who did or did not have a hypotensive disorder supporting previous theories that OH in older people is a multisystem decompensation rather than down to a single aetiological factor [18, 19] .
Conservative management
Non-drug therapies are the first-line option for most people with OH and include water-drinking, compression hosiery, withdrawal of provoking agents and physical counter-manoeuvres. There is little in the way of recent or New Horizons in orthostatic hypotension high-quality evidence for these therapies. However, a recent systematic review of 23 studies reached the following conclusions [21] :
• Home-based resistance training does not improve orthostatic BP in older people.
• Compression (30 mm Hg of pressure) of the lower limb (ankle to hip) improves orthostatic BP and symptoms in older people.
• Although not specific to older people, physical countermanoeuvres can improve orthostatic BP and symptoms.
• Sleeping with head up does not appear to be effective at improving orthostatic BP or symptoms.
• Bolus water-drinking may improve orthostatic BP in people with neurogenic OH.
• Eating smaller, more frequent meals improves symptoms in people with neurogenic OH.
Comprehensive geriatric assessment
In addition to the aforementioned measures, a Comprehensive Geriatric Assessment (CGA) may both prevent and improve OH. In a subgroup analysis of the GeMS study (Geriatric Multidisciplinary Strategy for the Good Care of the Elderly), 695 Finnish people, aged ≥75 years, were randomised to annual CGA or to usual care, 96% resided in their own home. Over the following 3 years, compared to baseline there was a 7% reduction in the prevalence of OH in the CGA cohort compared to an increase of 8% in the standard care group [22] . The main effect seems to have been the significantly greater rate of stopping causative drugs in those with OH undergoing CGA, however the precise mechanism is unknown. One limitation of this study was a higher prevalence of diabetes in the usual-care group, which may explain the increase in OH at follow-up.
Medication withdrawal
Although international guidelines and expert consensus documents recommend the withdrawal of provoking agents, over 250 medications are reported to cause OH [7, [23] [24] [25] . Fortunately, the 2011 international consensus statement recommends focussing on six principle classes of medication (Table 1 ) [7] .
There have been a few recent studies examining the association between antihypertensives and OH [26] [27] [28] [29] . Although these studies support this association, their observational nature limits their impact on clinical practice. For an in depth review of these studies we recommend a recent publication by Tan's group [30] .
Randomised evidence for the withdrawal of medication as a treatment option is now available from a post-hoc, subgroup analysis of the Discontinuation of Antihypertensive treatment in Elderly (DANTE) Study [31] . All 162 community-dwelling participants (aged ≥75 years) had hypertension (<160 mm Hg systolic), cognitive impairment (but not dementia) and OH (diagnosed on standing from a sitting position). They were randomised to either continue or discontinue antihypertensive medications and a repeat sit-to-stand BP was measured at 4-month follow-up. In a per-protocol analysis, limited to those who stopped all antihypertensives, there was a significantly greater reduction in the prevalence of OH [to 28/46 (40%), P = 0.001], however, numbers were small and the diagnosis of OH was not based on recommended methods. Furthermore, when performing the intention to treat analyses, the prevalence of OH was statistically similar between groups (50% in discontinuation, 62% in continuation, P = 0.13).
More recently, the Systolic blood PRessure Intervention Trial (SPRINT) has clouded the issue further [32] . This study a Over 250 medications are reported to cause OH. Those listed are considered causative medications by international consensus [7] . randomised 9,361 hypertensive participants (28% aged ≥75 years) to either an intensive BP target of (<120 mm Hg) or standard target (<140 mm Hg). The eligibility criteria were complex, extensive and excluded those with a standing systolic BP < 110 mm Hg. Interestingly, over 12 months the prevalence of OH in the intensive group was 16.6%, significantly lower than in the standard group (18.3%, P = 0.01). However, in those aged ≥75 years, there was no difference in the prevalence of OH (21 and 21.8%, P = 0.53) between groups.
The results of these studies do little to reduce the uncertainty regarding the withdrawal of medication for the treatment of OH.
Pharmacological management
Pharmacological therapy should be considered when nondrug therapies fail to improve symptoms adequately. Eighteen agents were identified in Logan and Witham's 2012 systematic review [33] . This well-conducted comprehensive review confirmed that there is a lack of good quality evidence for the pharmacological management of OH and concluded that many commonly used agents have not demonstrated beneficial effects on BP or symptoms. Below, we present recent evidence, relevant regulatory and licencing changes and emerging pharmacological agents.
Fludrocortisone
Fludrocortisone, a synthetic mineralocortoid, promotes renal sodium uptake, thereby expanding plasma volume. It also appears to sensitise alpha-adrenoceptors [34] . Although there are no recent trials evaluating the efficacy of fludrocortisone in OH, NICE produced an evidence summary in 2013 because of its frequent off-label use [35] . This summary was based on three randomised trials, one of which was in people with chronic fatigue syndrome who may or may not have had OH. The resulting evidence from 123 individuals (23 of whom we can be certain have OH), describes a significant improvement in tilt-table BP and autonomic symptoms but highlights that the long-term effects and safety are unknown. The European Federation of Neurological Sciences (EFNS) recommend a dose of 100-200 µg, in conjunction with adequate fluid and dietary salt [36] . Doses higher than this should be used with caution and it should be avoided in those with hypoalbuminaemia or congestive cardiac failure. Its actions may result in hypokalaemia and supine hypertension, and as such, monitoring of serum potassium and supine BP is recommended [24] . There are no registered clinical trials currently evaluating the use of fludrocortisone for OH in the WHO clinical trial registry.
Midodrine
The evidence base supporting the use of this alphaadrenoceptor agonist, for people with OH has consistently been graded as low or very low in systematic reviews [33, 37] .
A recent meta-analysis of adults with neurogenic OH, found that midodrine had no effect on systolic BP drop when compared to placebo [four studies, 161 participants, difference in means (MD): −4.9 (95% confidence interval: −25.9, 16.0), P = 0.645, I
2 95%]. However, there was an improvement in patient-reported global symptoms [two studies, 208 participants, MD: 0.7 (95% CI: 0.3, 1.1), P < 0.001, I
2 97%]. Given the risk of bias of the included studies, and the high levels of heterogeneity the authors graded the evidence for midodrine as low. Despite this, early in 2015 the UK MHRA granted a licence to Brancaster Pharma for its drug Bramox (midodrine hydrochloride) for people with severe, neurogenic OH that had failed to respond to other treatments. This makes midodrine the only licenced pharmacological agent for the treatment of OH in the UK.
Doses typically start at 2.5 mg once or twice per day, increasing as required to 10 mg three times per day [24] . The first dose should usually be taken one hour before rising (30 min for absorption and 30 min to be metabolised to the active form-desglymidodrine). The final dose should be taken approximately 4 h before recumbency to avoid supine hypertension, which may occur in 25% of users. It should be avoided in those with liver disease, severe heart disease, acute kidney injury, urinary retention, phaeochromocytoma and thyrotoxicosis [38] .
Ongoing clinical trials of midodrine include one US Study evaluating the efficacy of midorine in people with PD and orthostatic intolerance, and a Korean study in which people with OH are randomised to midodrine, pyridostigmine or midodrine with pyridostigmine [39, 40] .
Droxidopa
Droxidopa is an oral prodrug, metabolised by DOPA decarboxylase into noradrenaline [41] . It has been used to treat neurogenic OH in Japan for decades, but only recently has been approved by the FDA in the US [42] . There have been several randomised trials demonstrating a degree of efficacy. A recent meta-analysis, which includes four randomised controlled trials of 494 people with neurogenic OH (aged 18-92 years) concluded that there is a moderate level of evidence for the use of droxidopa in reducing dizziness [MD: −0.97 (95% CI: −1.51, −0.42), p < 0.001, I
2 0%] and improving daily activity [MD: −0.86 (95% CI: −1.34, −0.38), P < 0.001, I
2 10%] [43] . The effect on standing systolic BP was relatively small, with inconsistent results between studies [MD: 3.9 (95% CI: 0.1, 7.69), P 0.04, I
2 10%]. Risk of bias was present in all included studies which were funded by industry and used highly selective inclusion criteria.
There are current ongoing studies assessing the longterm efficacy and safety; side effects include headache (11%), dizziness (8%) and fatigue (6%) and it should be avoided in people with hypertension (180/110), significant cardiac, hepatic or renal disease and in people taking norepinephrine uptake inhibitors or tricyclic antidepressants [43, 44] . Starting dose is 100 mg three times daily, titrated
New Horizons in orthostatic hypotension
to maximum dose of 600 mg three times daily. It is not yet widely available in Europe.
Emerging agents
Better known for its use in attention deficit hyperactivity disorder, atomoxetine is a noradrenaline reuptake inhibitor which exerts a vasopressor effect, with hypertension developing in 10% of users [45] . In a recent proof of concept study, 65 people (aged 65 ± 9 years) with severe, neurogenic OH were randomised to a single dose of midodrine, atomoxetine or placebo [46] . While both midodrine and atomoxetine increased standing systolic BP, the increase was much more pronounced with atomoxetine [20 (13-27) mm Hg, MD: 7.5 (95% CI: 0.6, 14.5), P = 0.03]. Atomoxetine also resulted in a slight improvement in dizziness when compared to placebo [MD: 0.6 (95% CI: −0.1, 1.7), P = 0.03], but not when compared to midodrine (P = 0.42). Further clinical trials are required before considering this agent for use in clinical practice. Mirabegron is a beta-3 adrenergic receptor agonist licenced for the treatment of overactive bladder (OAB). Given its stimulatory effects on the cardiovascular system, it has been considered a potential agent for the treatment of OH. Anecdotally, it has been used in people with OAB and OH as a means of avoiding the vasodepressor effects of anticholinergic alternatives. However, the UK MHRA has recently issued a drug safety update concerning the risk of severe hypertension with mirabegron [47] . In the absence of evidence for use in OH, the risks and benefits should be clearly discussed with patients. There is one planned study of mirabegron in people with PD and OAB which will evaluate the effects on OH as a secondary outcome [48] .
New agents currently under early-phase evaluation include TD-9855 (Theravance Biopharma R&D, Inc.), a novel noradrenaline and serotonin reuptake inhibitor, currently undergoing phase 2 studies in 30 people with neurogenic OH [49] . Further information on this experimental drug is limited, although it appears to have had limited success for the treatment of fibromyalgia-associated pain with high rates of adverse events [50] .
A planned future study of a rather idiosyncratic intervention, intends to evaluate the effects of 'dawn simulation' (using light therapy) on reducing the postural drop in BP on first standing in the morning [51] . The hypothesis is that a gradual arousal the nervous system, by mimicking dawn, will stimulate and prepare the cardiovascular system before rising. The study will recruit 36 adults aged 55-85 years with a history of dizziness or falls on rising.
Prognosis
The natural history of OH is not well-defined, particularly for those with initial OH. However, studies have previously described the increased risk of cardiovascular events and increase in mortality. The results of these studies have recently been pooled in a meta-analysis (13 studies, 121 913 individuals) [3] . It confirms a significantly increased 5-year mortality [relative risk 1.5 (95% CI: 1.24, 1.81), I
2 93%], however, the significance reduced when focussing on those aged over 65 years [1.26 (95% CI: 0.99, 1.62)].
The significance of delayed OH has been unknown until very recently. The hypothesis that it represented a partial dysautonomia now looks likely in light of recent evidence. A 10-year follow-up of 48 cases, from a specialist autonomic clinic (mean age: 51 years), with delayed OH found that 54% of cases progressed to OH within three minutes. Interestingly, one third also developed an alpha-synuclieopathy during follow-up (PD, dementia with Lewy bodies, multisystem atrophy and pure autonomic failure). A 10-year mortality for delayed OH was 29% (9% in controls, 64% in those with OH at baseline) [52] .
Conclusion
OH is a common condition associated with a reduced quality of life and increase in mortality. Existing diagnostic criteria appear adequate and are supported by recent evidence. There is some evidence that conservative measures can improve orthostatic BP and symptoms although these may be limited by adherence and acceptability. Midodrine is now the only licenced medication for OH in the UK. There are several ongoing studies evaluating the effects of some newer pharmacological agents, however, whether the results can be easily applied to older people remains to be seen.
Keypoints
• Diagnostic criteria now exist for initial and delayed orthostatic hypotension, as well as orthostatic hypotension in hypertension.
• Comprehensive Geriatric Assessment appears to reduce to prevalence of orthostatic hypotension.
• Midodrine is now the only licenced medicine for orthostatic hypotension in the UK.
• Emerging treatments under evaluation include droxidopa and atomoxetine.
• It remains unclear whether withdrawal of antihypertensives improves orthostatic hypotension.
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